IP Verse

Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate

Patent No. EP2508188 (titled "Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate") was filed by Astrazeneca on Mar 21, 2008. The application was issued on May 10, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GALENICUM HEALTH SLUFeb 9, 2024GALENICUM HEALTH SLU
GEDEON RICHTERFeb 9, 2024DR SCHON
GENERICS UKFeb 9, 2024TER MEER STEINMEISTER & PARTNER
KRAUS & LEDERER PARTGMBBFeb 9, 2024KRAUS & LEDERER PARTGMBB
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBFeb 6, 2024SONNENHAUSER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2508188

ASTRAZENECA
Application Number
EP12153939A
Filing Date
Mar 21, 2008
Status
Granted And Under Opposition
Apr 7, 2023
Publication Date
May 10, 2023
External Links
Slate, Register , Google Patents